Antonella Farina
A5088035856- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Chronic Lymphocytic Leukemia Research
- Dermatology and Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Toxin Mechanisms and Immunotoxins
- Biosimilars and Bioanalytical Methods
- Computational Drug Discovery Methods
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for treatment of rheumatoid arthritis (RA). However, data on retention rate TOFA therapy are still far from definitive. Objective: The goal this study is add new real-world in a cohort RA patients followed long period time. Methods: A multicenter retrospective subjects treated with as monotherapy or combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) conducted 23 Italian...
Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, US Food Drug Administration (FDA) raised concerns about safety TOFA after its approval. This prompted European Medicines Agency (EMA) to issue two warnings limiting use, then extended a third warning all JAKi in patients at high risk developing serious adverse effects (SAE). These...
To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response PsA patients and analyze the predictors clinical response.All consecutive treated with fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, disease activity at baseline, 6 months, 12 months...
Background and Objectives: The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related cardiovascular cancer risks, prompted need additional investigation in real-world clinical settings. This...
Introduction: Upadacitinib (UPA) is an oral Janus kinase inhibitor (JAKi) recently approved for the treatment rheumatoid arthritis (RA) treatment. Although registrational studies have demonstrated efficacy of UPA in RA, data on long-term retention rate this drug are still lacking. Objective: The objective his study was to evaluate real-world patients with analyze possible reasons discontinuation, and attempt identify independent factors possibly associated persistence Methods: We conducted a...
Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important choose most effective treatment according patients' characteristics. Apremilast recommended in PsA with moderate activity. In clinical practice, suitable patients for apremilast are those affected by peripheral oligo-articular arthritis. However, not so straightforward definitely identify this phenotype. Musculoskeletal ultrasound (MUS) good tool detecting...
Enthesitis and dactylitis are difficult-to-treat features of psoriatic arthritis (PsA), leading to disability affecting quality life. The aim this study is evaluate enthesitis (using the Leed index (LEI)) at 6 12 months in patients treated with apremilast. Patients affected by PsA from fifteen Italian rheumatological referral centers were screened. inclusion criteria were: (a) or dactylitisphenotype; (b) treatment apremilast 30 mg bid. Clinical history, including disease activity, recorded....